Hostname: page-component-745bb68f8f-kw2vx Total loading time: 0 Render date: 2025-01-08T22:39:46.789Z Has data issue: false hasContentIssue false
  • English
  • Français

Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression

Published online by Cambridge University Press:  09 July 2009

V. O'Keane ,
K. O'Flynn ,
J. Lucey  and
T. G. Dinan
V. O'Keane
Affiliation:
Trinity College Medical School, St James's Hospital, Dublin, Ireland
K. O'Flynn
Affiliation:
Trinity College Medical School, St James's Hospital, Dublin, Ireland
J. Lucey
Affiliation:
Trinity College Medical School, St James's Hospital, Dublin, Ireland
T. G. Dinan*
Affiliation:
Trinity College Medical School, St James's Hospital, Dublin, Ireland
*
1 Address for correspondence: Dr Ted Dinan, Psychiatric Unit, St James's Hospital, Dublin 8, Ireland.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Theorists have extrapolated the cholinergic supersensitivity theory of affective disorder from a convincing and broad spectrum of clinical observation and research. This hypothesis is tested using a neuroendocrine probe approach with the challenge drug pyridostigmine, an indirect cholinergic agent thought to release growth hormone (GH) by decreasing inhibitory somatostatin tone. The consequent increments in plasma GH were considered to reflect central acetylcholine responsivity. Fifty-four volunteers were tested: 27 DSM-III-R major depressives (18 women and 9 men) and 27 age- and sex-matched healthy controls. Subjects were cannulated at 9.00 h following an overnight fast and two baseline samples were taken at 15 min intervals. Pyridostigmine 120 mg was administered orally and thereafter samples were taken at the time points +60, +90, +120 and +180 min. GH responses were significantly greater in depressives than controls and this effect was more marked for men than women. These results support the proposal that muscarinic upregulation and/or supersensitivity is associated with depression.

Type
Original Articles
Information
Psychological Medicine , Volume 22 , Issue 1 , February 1992 , pp. 55 - 60
Copyright
Copyright © Cambridge University Press 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Referemces

American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. American Psychiatric Association: Washington, DC.Google Scholar
Berger, M., Riemann, D., Hochli, D. & Spiegel, R. (1989). The cholinergic rapid eye movement sleep induction test with RS 86. Archives of General Psychiatry 46, 421–428.CrossRefGoogle ScholarPubMed
Carney, M. W., Heninger, G. R. & Steinberg, D. E. (1965). The diagnosis of depressive symptoms and the prediction of ECT response. British Journal of Psychiatry 140, 659–674.CrossRefGoogle Scholar
Carroll, B. J., Greden, J. & Haskett, R. (1980). Neurotransmitter studies of neuroendocrine pathology in depression: Biogenic Amines Symposium, London, England. Acta Psychiatrica Scandinavica 61 (suppl), 183–200.CrossRefGoogle Scholar
Casanueva, F. F., Villanueva, L., Cabranes, J. A., Cabezas, J. & Fernandez, A. (1984). Cholinergic mediation of growth hormone secretion elicited by arginine, clonidine and physical exercise in man. Journal of Clinical Endocrinology and Metabolism 59, 526–530.CrossRefGoogle ScholarPubMed
Casanueva, F. F., Villanueva, L., Cordido, Y., Diaz, J. A., Cabranes, R., Spiegel, R. & Dieguez, C. (1989). Differential effects of direct and indirectly acting cholinergic agonists on growth hormone release in man, and lack of effect on cortisol secretion. Journal of Neuroendocrinology 1, 379–382.CrossRefGoogle ScholarPubMed
Cordido, F., Casanueva, F. F. & Dieguez, C. (1989). Cholinergic receptor activation by pyridostigmine restores GH responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. Journal of Clinical Endocrinology and Metabolism 68, 290–293.CrossRefGoogle ScholarPubMed
Cordido, F., Dieguez, C. & Casanueva, F. F. (1990). Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine or hypoglycaemia in normal and obese subjects. Journal of Clinical Endocrinology and Metabolism 70, 1361–1370.CrossRefGoogle ScholarPubMed
Crawshaw, J. A. & Mullen, P. E. (1984). A study of benzhexol addiction. British Journal of Psychiatry 145, 300–303.CrossRefGoogle Scholar
Dilsaver, S. C. (1986). Pathophysiology of ‘cholinoceptor supersensitivity’ in affective disorders. Biological Psychiatry 21, 813–829.CrossRefGoogle ScholarPubMed
Dilsaver, S. C. & Greden, F. G. (1984). Antidepressant withdrawal-induced activation (hypomania and mania): mechanism and theoretical significance. Brain Research Reviews 7, 29–48.CrossRefGoogle Scholar
Dilsaver, S. C., Feinberg, M. & Greden, J. F. (1983 a). Antidepressant withdrawal symptoms treated with anticholinergic agents. American Journal of Psychiatry 140, 249–251.Google ScholarPubMed
Dilsaver, S. C., Kronfol, Z., Greden, J. F. & Sackellares, J. C. (1983 b). Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. Journal of Clinical Psychopharmacology 3, 157–164.CrossRefGoogle ScholarPubMed
Dinan, T. G., Barry, S., Yatham, L. N., Mobayed, M. & O'Hanlon, M. (1990). The reproducibility of the prolactin response to buspirone: relationship to the menstrual cycle. International Clinical Psychopharmacology 5, 119–123.CrossRefGoogle ScholarPubMed
Ellis, J. & Lenox, R. H. (1990). Chronic lithium treatment prevents atropine-induced supersensitivity of the muscarinic phosphoinositide response in rat hippocampus. Biological Psychiatry 28, 609–619.CrossRefGoogle ScholarPubMed
Gershon, S. & Shaw, F. H. (1961). Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet i, 1371–1374.CrossRefGoogle Scholar
Giustina, A., Bossoni, S., Cimino, A., Pizzocolo, G., Romanelli, G. & Wehrenberg, W. B. (1990). Impaired growth hormone (GH) responses to pyridostigmine in type 1 diabetic patients with exaggerated GHRH-GH-stimulated GH secretion. Journal of Clinical Endocrinology and Metabolism 71, 1486–1490.CrossRefGoogle ScholarPubMed
Grob, D., Harvey, A. M., Langworthy, O. R. & Lilenthal, J. L. (1947). The administration of diisopropylfluorophosphate (DFP)) to man. Johns Hopkins Hospital Bulletin 81, 257–266.Google ScholarPubMed
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23, 56–62.CrossRefGoogle ScholarPubMed
Janowsky, D. S., Davis, J. M., El-Yousef, H. & Sekerke, H. J., (1972). A cholinergic-adrenegic hypothesis of mania and depression. Lancet ii, 632–635.CrossRefGoogle Scholar
Janowsky, D. S., Risch, S. C., Ziegler, M. G., Gillan, J. C., Huey, L. & Rausch, J. (1986). Physostigmine-induced epinephrine release in patients with affective disorder. American Journal of Psychiatry 143, 919–921.Google ScholarPubMed
Jarrett, D. B., Miewald, J. M. & Kupfer, D. J. (1990). Recurrent depression is associated with a persistent reduction in sleep-related growth hormone secretion. Archives of General Psychiatry 47, 113–118.CrossRefGoogle ScholarPubMed
Kramer, J. C., Klein, D. F. & Fink, M. (1961). Withdrawal symptoms following discontinuation of imipramine therapy. American Journal of Psychiatry 118, 549–550.CrossRefGoogle Scholar
Krishnan, K. R. R., Manepalli, A. N., Ritchie, J. C., Rayasam, K., Melville, M. L., Daughtry, G., Thorner, M. O., Rivier, J. E., Vale, W. W., Nemeroff, C. & Carroll, B. J. (1988). Growth-hormone releasing factor stimulation test in depression. American Journal of Psychiatry 145, 90–92.Google ScholarPubMed
Layman, J. M. & Milton, A. S. (1971). Some actions of Δ-tetrahydrocannabinol and cannabionoids at cholinergic functions. British Journal of Pharmacology 41, 379p–380p.Google Scholar
Lesch, K. P., Laux, G., Pfuller, H., Erb, A. & Beckmann, H., (1987). Growth hormone response to GH-releasing hormone in depression. Journal of Clinical Endocrinology and Metabolism 65, 1278–1281.CrossRefGoogle ScholarPubMed
Locatelli, V., Torsello, A., Redaelli, E., Ghigo, E., Massara, F. & Muller, E. E. (1986). Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone – releasing hormone in the rat: evidence for mediation by somatostatin. Journal of Endocrinology 111, 271–278.CrossRefGoogle ScholarPubMed
McEwan, B. S. (1988). Basic research perspective: ovarian hormone influence on brain neurochemical functions. In Contemporary Issues in Obstetrics and Gynaecology, vol. 2 (ed. Gise, L. H.), pp. 21–33. Churchill Livingstone: New York.Google Scholar
Massara, F., Ghigo, E., Molinatti, P., Mazza, E., Locatelli, V. & Muller, E. E. (1986). Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. Acta Endocrinologica 113, 12–16.Google ScholarPubMed
Mendlewicz, J., Linkowski, P., Kerkhofs, M., Desmedt, D., Golstein, J., Copinschi, G. & Van Canter, E. (1985). Diurnal hypersecretion of growth hormone in depression. Journal of Clinical Endocrinology and Metabolism 60, 505–512.CrossRefGoogle ScholarPubMed
Merimee, T. J. & Fineberg, S. E. (1971). Studies of the sex based variation of human growth hormone secretion. Journal of Clinical Endocrinology and Metabolism 33, 896–902.CrossRefGoogle ScholarPubMed
Nordberg, A. & Sundwall, A. (1977). The effect of sodium pentobarbitol on the apparent turnover of acetylcholine in different brain regions. Acta Physiological Scandinavia 99, 336–344.CrossRefGoogle Scholar
O'Keane, V., O'Hanlon, M., Webb, M. & Dinan, T. G. (1991). d-Fenfluramine/prolactin response throughout the menstrual: evidence for an oestrogen-induced alteration. Clinical Endocrinology 34, 289–292.CrossRefGoogle ScholarPubMed
Peabody, C. A., Warner, M. D. & Markoff, E. (1990). Growth hormone to growth releasing hormone in depression and schizophrenia. Psychiatric Research 33, 269–276.CrossRefGoogle ScholarPubMed
Pullen, G. P., Best, N. R. & Maguire, J. (1984). Anticholinergic drug abuse. A common problem? British Medical Journal 289, 612–613.CrossRefGoogle ScholarPubMed
Risch, S. C. (1982). β-endorphin hypersecretion in depression: possible cholinergic mechanisms. Biological Psychiatry 17, 1071–1079.Google ScholarPubMed
Risch, S. C., Cohen, P. M. & Janowsky, D. S. (1981). Physostigmine induction of depressive symptomatology in normal human subjects. Journal of Psychiatric Research 4, 89–94.CrossRefGoogle ScholarPubMed
Ross, R. J., Tsagarakis, S., Grossman, A., Nhagafoong, S., Touzel, R. J., Rees, L. H. & Besser, G. M. (1987). GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clinical Endocrinology 27, 727–733.CrossRefGoogle ScholarPubMed
Rubin, R. T., Poland, R. E. & Lesser, I. M. (1990). Neuroendocrine aspects of primary endogenous depression X: serum growth hormone measures in patients and matched control subjects. Biological Psychiatry 27, 1065–1082.CrossRefGoogle ScholarPubMed
Sitaram, N., Mendelson, W. B., Wyatt, R. J. & Gillin, J. C. (1977). The time dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Research 122, 562–567.CrossRefGoogle ScholarPubMed
Sitaram, N., Nurnberger, J. I., Gershon, E. S. & Gillin, J. C. (1982). Cholinergic regulation of mood and REM sleep: potential marker of vulnerability to affective disorder. American Journal of Psychiatry 139, 571–576.Google ScholarPubMed
Tabakoff, B., Muroz-Marcus, M. & Fields, J. Z. (1979). Chronic ethanol feeding produces an increase in muscarinic cholinergic receptors in mouse brain. Life Sciences 25, 2173–2180.CrossRefGoogle ScholarPubMed
Thomas, R., Beer, R., Harris, B., John, R. & Scanlon, M. (1989). GH responses to growth hormone releasing factor in depression. Journal of Affective Disorders 16, 133–137.CrossRefGoogle ScholarPubMed
Wager, S., Robinson, D., Goetz, R., Nunes, E., Gully, R. & Quitkin, F. (1990). Cholinergic REM sleep induction in atypical depression. Biological Psychiatry 27, 441–446.CrossRefGoogle ScholarPubMed
Wahlstrom, G. & Nordberg, A. (1979). Sensitivity to an active synaptosomal uptake of choline in the abstinence after chronic barbital treatments. Acta Physiologica Scandinavica (suppl) 473, 165–203.Google Scholar